MDGL Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Madrigal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$308.44 |
| 52 Week High | US$368.29 |
| 52 Week Low | US$168.25 |
| Beta | -0.40 |
| 1 Month Change | -11.23% |
| 3 Month Change | 36.65% |
| 1 Year Change | 31.21% |
| 3 Year Change | 253.47% |
| 5 Year Change | 230.84% |
| Change since IPO | 2,938.79% |
Recent News & Updates
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Nov 03Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
Nov 02
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Oct 24Recent updates
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Nov 03Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
Nov 02Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Oct 24Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher
Aug 09While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal: NASH Data In Q4 Is The Key
Apr 19Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09Shareholder Returns
| MDGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | -3.6% | -2.4% |
| 1Y | 31.2% | -2.7% | 23.3% |
Return vs Industry: MDGL exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: MDGL exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| MDGL volatility | |
|---|---|
| MDGL Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDGL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDGL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 376 | Bill Sibold | www.madrigalpharma.com |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Fundamentals Summary
| MDGL fundamental statistics | |
|---|---|
| Market cap | US$6.73b |
| Earnings (TTM) | -US$518.67m |
| Revenue (TTM) | US$76.81m |
87.6x
P/S Ratio-13.0x
P/E RatioIs MDGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDGL income statement (TTM) | |
|---|---|
| Revenue | US$76.81m |
| Cost of Revenue | US$2.79m |
| Gross Profit | US$74.03m |
| Other Expenses | US$592.70m |
| Earnings | -US$518.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.78 |
| Gross Margin | 96.37% |
| Net Profit Margin | -675.24% |
| Debt/Equity Ratio | 15.1% |
How did MDGL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Madrigal Pharmaceuticals, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Jason Zemansky | BofA Global Research |
| Alexandria Hammond | BofA Global Research |